SB202190 (FHPI)

Catalog No.S1077

SB202190 (FHPI) Chemical Structure

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • C, Jurkat cells with SB202190 at 1, 5, and 10 μM were tested, and a decreased SRP72 expression was found when using at 10 μM (lanes 8 and 9). D, results were analyzed and RUA illustrated, finding significant results at 10 μM at 240 versus 0 and 120 versus 0 min (p<0.05).

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

    C, effect of SB202190 (1, 5, and 10 μM) on SRP72 phosphorylation was tested. A decreased intensity of SRP72 expression when used at 1 μM (240 min) and 5 and 10 μM (120 and 240 min) was found. D, RUA illustrated obtaining significant results at concentration 5 and 10 μM at 120 versus 0 and 240 versus 0 min. * indicates p<0.05.

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

  • We used real time RT-PCR to investigate the effects of SB202190 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.
Targets
p38α [1]
(Cell-free assay)
p38β [1]
(Cell-free assay)
50 nM 100 nM
In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. [2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. [3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). [4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. [6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT-116 NVvvXpBjTnWwY4Tpc44hSXO|YYm= NInrWHYzPSEQvF2= M1y3[lMxKG2rbh?= NX62c5RoTE2VT9Mg M174[IF1fGWwdXH0[ZMhfGinIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbjDv[kBpSkRvMjDpckBz\XOyb37zbZZmKHSxIFTB MnfuNlYzOjN{NUG=
MDA-MB-231 NFfjTIlHfW6ldHnvckBCe3OjeR?= NUDNbJFHOiEQvF2= NH;LUlgzPCCq M3K0bYxme3OnbnXzJGNEVDJiaX7keYN1cW:wIHL5JHRPTs7z M3PxNlI3OTByOES4
rBMSCs M{LaSmZ2dmO2aX;uJGF{e2G7 NFuyR5cyOCEQvF2= NVn6WI1ROi53IHi= Mmrt[IVxemW|c3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiRWLLJIFv\CCyM{i= MYeyOlA2OzJ4Nh?=
MG63 NWS1dJh5TnWwY4Tpc44hSXO|YYm= MWGxNE8zOC9|MDFOwG0> NFrve3ozPCCq MYDzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgcIV3\Wxib3[gdIhwe3Cqb4L5cIF1\WRicEO4JIlv\HWlZXSgZpkhS2SFbEKgbY4h[SClb37j[Y51emG2aX;uJE1l\XCnbnTlcpQhdWGwbnXy MXOyOVk6QDNzMh?=
MG63 MXjBdI9xfG:|aYOgRZN{[Xl? M{TRVFExNzJyL{OwJO69VQ>? NHLFbXQzPCCq M{DHd5Nq\26rZnnjZY51dHliZHXjdoVie2WmIITo[UBieG:ydH;zbZMhemG2ZTDv[kBOTzZ|IHnu[JVk\WRiYomgR4REdDJ? MVyyOVk6QDNzMh?=
HTSMCs MWPGeY5kfGmxbjDBd5NigQ>? MnP3NE4yNzFxMUCg{txO NH7mU|kyKGh? M2S3folvcGmkaYTl[EBEV1KPLUKtbY5lfWOnZDDIU{0yKHC{b4TlbY4hdGW4ZXzzJIFv\CCvUl7BJIV5eHKnc4Ppc44> NV3GXnVwOjV7MkG0OlQ>
MIA PaCa-2 M3XYcGZ2dmO2aX;uJGF{e2G7 M164WlIxyqEQvF2= MViyOEBp M4fBb5Jm\HWlZXSgcIFkfGG2ZTDhZ4N2dXWuYYTpc44hcW5iY3;tZolv[XSrb36ge4l1cCCkb4ToJFIuTEdiYX7kJGQu[Wyub4PlxsA> MUWyOVg5QDR6OR?=
MIA PaCa-2 M{e1[mZ2dmO2aX;uJGF{e2G7 NYn4NlZEOjEEoN88US=> NWjVSYs4OjRiaB?= M2H4PZJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u MmG2NlU5QDh2OEm=
BxPC-3 MYPGeY5kfGmxbjDBd5NigQ>? MkXaNlDDqM7:TR?= MYOyOEBp MVPy[ZN2dHS|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?= MYiyOVg5QDR6OR?=
AsPC-1 MlPUSpVv[3Srb36gRZN{[Xl? MW[yNOKh|ryP NYTHNmJqOjRiaB?= NXexdnh4emW|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44> NY\OSpAyOjV6OEi0PFk>
MIA PaCa-2 M1LxOGZ2dmO2aX;uJGF{e2G7 Ml;zNlDDqM7:TR?= M1HMVVI1KGh? NHvzU2ZmdmijbnPld{BkdGWjdnHn[UBw\iCSQWLQJJdp\W5iY3;tZolv\WRid3n0bEBodHWlb4PlJIFv[WyxZ4O= MmfQNlU5QDh2OEm=
MIA PaCa-2 NUD5R3VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTLNlDDqM7:TR?= M17ubVIhcA>? MlHTd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm NXLIdnZYOjV6OEi0PFk>
BxPC-3 M1jUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIqy[YQzOMLizszN MVWyJIg> Mlvud4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm MVWyOVg5QDR6OR?=
AsPC-1 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmyNOKh|ryP MVGyJIg> M3rwWpNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? MornNlU5QDh2OEm=
HEY MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonENlDDqM7:TR?= NHzJTXkzKGh? M1jmZZNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? MmPENlU5QDh2OEm=
OVCAR-3 NX\zWIhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXnTVdwOjEEoN88US=> MkPuNkBp MV7z[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> MkL0NlU5QDh2OEm=
SK-OV-3 NHHoXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LxNlIxyqEQvF2= NHPJTXMzKGh? NGrkOGF{\W6|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V? MYKyOVg5QDR6OR?=
MH7A  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjsT41yOjRiaB?= NES4O4hz\WmwZn;yZ4V{KHSqZTDpcohq[mm2b4L5JIVn\mWldIOgc4YhYEGQ NYKwOGlmOjV6NkK5OlY>
MH7A  MlW5RZBweHSxc3nzJGF{e2G7 NEPPVY8zPSEQvF2= MljoNlQhcA>? NYXWfHlmemW4ZYLz[ZMh[2WubDDjfYNt\SCjcoLld5QhcW6mdXPl[EBjgSC[QV6gZY5lKGOjdYPl[EBieG:ydH;zbZMhd2ZiY3XscJMhfmmjIHHjeIl3[XSrb36gc4YhUk6N MV2yOVg3Ojl4Nh?=
SCC25 M2X4[WZ2dmO2aX;uJGF{e2G7 NV30cHB5OjBizszN MV6yOEBp MXvpcoNz\WG|ZYOgZZV1d3CqYXf5JIxmfmWu MWqyOVg{PDRyMB?=
HaCaT  NUH2[2hFTnWwY4Tpc44hSXO|YYm= MUe1JOK2VQ>? MWqyOEBp Mn;LbY5pcWKrdIOgTWZPNc7|LXnu[JVk\WRiQ1PMNlIheHKxZIXjeIlwdiCuZY\lcJM> MXiyOVg{PDN3Mx?=
HaCaT  NH31fGZHfW6ldHnvckBCe3OjeR?= NG\PU3M2KML3TR?= M1LCTlI1KGh? MUDpcohq[mm2czDJSm4u|rFvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=> NFWyeokzPTh|NEO1Ny=>
HPAEpiCs  M1nCO2Z2dmO2aX;uJGF{e2G7 MmTvNU8{NzFyIN88US=> MkTxNUBp MXzy[YR2[2W|IGOxVE1qdmS3Y3XkJGlESU1vMTDwdo91\WmwIHHu[EBuWk6DIHX4dJJme3Orb36gZY5lKHC{b33veIVzKGGldHn2bZR6 NIPUNYwzPTd|NEmwNC=>
HPAEpiCs NIW3SoRHfW6ldHnvckBCe3OjeR?= MU[xM|MwOTBizszN M1vq[lEhcA>? M3PzRYlvcGmkaYTzJHMyWC2|dHnteYxifGWmIFHreEBxcG:|cHjvdplt[XSrb36gJOKh MVGyOVc{PDlyMB?=
HPAEpiCs NIXUT2xHfW6ldHnvckBCe3OjeR?= MVmxM|MwOTBizszN MXqxJIg> M1HqUIlvcGmkaYTzJHMyWCC2aX3lMYRmeGWwZHXueIx6KHO2aX31cIF1\WRiYz3KeY4heGixc4Doc5J6dGG2aX;u MmDtNlU4OzR7MEC=
K562 MV3GeY5kfGmxbjDBd5NigQ>? MX2xNOKh|ryP M{nU[lHDqGh? NGjTZohFVVOR NWHrdoZscW6qaXLpeJMheXWrbnHjdolv\S2rbnT1Z4VlKHB|ODDNRXBMKHCqb4PwbI9zgWyjdHnvci=> M4nnU|I2Pjh2MESz
PANC-1 MljSSpVv[3Srb36gRZN{[Xl? M{PHfFExKM7:TR?= Mmr3NUBp Ml2y[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB? NGjQd5EzPTZ|MkKyNi=>
BxPC-3 Mn3XSpVv[3Srb36gRZN{[Xl? NGnJdW8yOCEQvF2= MoXFNUBp MU\lcohidmOnczD0bIUh[XW2b4DoZYdq[yCnZn\lZ5TDqA>? M3nUSlI2PjN{MkKy
K562  M1zMcmZ2dmO2aX;uJGF{e2G7 M4\CXFAvOjVvMTFOwG0> M17tO|I1KGh? M{G2ZZN2eHC{ZYPz[ZMhemW|dnXyZZRzd2xvaX7keYNm\CCKMlHYJJBpd3OyaH;yfYxifGmxbh?= Mlq2NlU3OTl|OUK=
THP-1 MnPUSpVv[3Srb36gRZN{[Xl? NHvtZow2KML3TR?= MlPjNkBp NVPv[3Eye2mpbnnmbYNidnSueTDheJRmdnWjdHXzJJNm[3KndHnvckBw\iCLTD2x{tEhcW6mdXPl[EBjgSB{N1;IR4hwdCCybIXzJGZUVC1zwrC= M4HFOlI2PTl6Nk[x
WB NGLJVndHfW6ldHnvckBCe3OjeR?= M3L2dVIx6oDLzszNxsA> M2W5blMx6oDLbXnu M3PNbIRm[3KnYYPld{B1cGViTGDTMUBweiCOVFGtbY5lfWOnZDDJUE03KGGwZDDUUmYu|rIEoIDyc4R2[3Srb36= MoTmNlU2OzB4OEK=
RAW 264.7 M4TFcWZ2dmO2aX;uJGF{e2G7 NXLZPXh4OTEEoN88US=> MVezNQKBkW2rbh?= M1TUXolv\HWlZYOgZ4hiemGldHXybZN1cWNidnHjeY9t[XSrb36gc4YhV0O|wrC= M1\CVlI2PDZzM{m5
RAW 264.7 NGG2epVHfW6ldHnvckBCe3OjeR?= MYWxNOKh|ryP NX\mRZMxOzEkgJntbY4> NWrPUIF[[XS2ZX71ZZRmeyC2aHWg[YZn\WO2czDv[kBQWEdib36gc5N1\W:lbHHzeEBz\XS{YXP0bY9v NX7XTWJlOjV2NkGzPVk>
HaCaT  NGLwOIpHfW6ldHnvckBCe3OjeR?= NULP[mE5PDEEoN88US=> M2\qdFMuOjRiaB?= MkTsSG1UVw>? MY\y[YR2[2W|IITo[UBi[2O3bYXsZZRqd25ib3[gXm8uOQ>? NEmwTo8zPTR|NUS4OS=>
H9c2 NEnOemdHfW6ldHnvckBCe3OjeR?= NFP0ZXc2OMLizszNxsA> M4rBeVEzKGh? M2C1[JJm\HWlZYOgUGRJKHKnbHXhd4Uh[W6mIF3NVEBtd3O| Mn3jNlUzPDV6MUi=
HSCs MUDBdI9xfG:|aYOgRZN{[Xl? M1rzfFI2KM7:TR?= M2G2W|I1yqCq M3XreZNq\26rZnnjZY51dHliYYT0[Y52[XSnczDUS{1qdmS3Y3XkJIFkfGm4YYTl[EBJW0O|IHHwc5B1d3Orcx?= M{P3XlI1QTZzOUWw
THP-1 M3vtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf3UoY4OiCq NXXLWI9vTE2VTx?= NFjidlRKSzVyPUSuO:69VQ>? MYeyOFgyPTB6Nx?=
MDDCs M3;teGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXOwOlFGPzJiaB?= MoKySG1UVw>? M1H6UGlEPTB{LkhOwG0> M3;s[VI1QDF3MEi3
MDDCs NHjNS3dHfW6ldHnvckBCe3OjeR?= MlTKNE0yPSEQvF2= Mki0OFghcA>? MXnEUXNQ NHHs[XZ{fXCycnXzd4V{KEmITj5OtUBidmRiSWCtNVAheHKxZIXjeIlwdsLi MX:yOFgyPTB6Nx?=
MDDCs MX7GeY5kfGmxbjDBd5NigQ>? MkK4NE0yPSEQvF2= Mo\GOFghcA>? MWHEUXNQ M{fRVolvcGmkaYTzJG1KWC1zYTygUWlRNTGkIHHu[EBTSU6WRWOgdJJw\HWldHnvci=> NFLnfpkzPDhzNUC4Oy=>
MDDCs M32wbGZ2dmO2aX;uJGF{e2G7 M1rGR|ExKM7:TR?= NVPMZYJPOy53IHi= NV7pVmxjTE2VTx?= MmjvZoxw[2u|IFXCU3YhT1BuIHL1eEBvd3RiVmPWJGchdWWmaXH0[YQh\W62comgbY51dyCqdX3hckBOTESFcx?= MmPxNlQ5OTVyOEe=
macrophages NVH6WWIzTnWwY4Tpc44hSXO|YYm= NWKydmt6OeLCid88US=> MUG0MlXjiImq NYG4S45C[2:vcHzleIVtgSCrbnjpZol1eyCPVD3JTWkucW6mdXPl[EBi[3SrdnH0bY9vKG:oIF7GMe67Sg>? MnXyNlQ5ODh4M{O=
PDL  MV;GeY5kfGmxbjDBd5NigQ>? M4PTVFIxyqEQvF5CpC=> M{nX[lMxKG2rbh?= NYDETlR1TE2VTx?= MYHzbYdvcW[rY3HueIx6KGmwaHnibZR{KHSqZTD0[Y5{cWynIH\vdoNmNW2nZHnheIVlKEKPUD2yJIV5eHKnc4Ppc44> NFrwVWIzPDV4MUC4NS=>
AGS M3rDfWZ2dmO2aX;uJGF{e2G7 NVvNcWZYPSEQvF2= MWWzNEBucW5? NXTCVGEye3WycILld5Nme8LiMT3pcoR2[2WmIHPhd5Bie2VvODDhcoQh[2G|cHHz[U0{KGGldHn2ZZRqd25? M4Lrb|I1PTR5OEe4
H520 M4jCd2Z2dmO2aX;uJGF{e2G7 MnPPNVDDqML3TR?= NXjsdGZpOSCq MVLEUXNQ NEDUe|ll\WO{ZXHz[ZMhfGinIIDlcYV1emW6ZXStbY5lfWOnZDDNV2gzKG2UTlGgZY5lKHC{b4TlbY4hdGW4ZXzz M3GyZlI1PTNyNEe1
H1703 M1PmOGZ2dmO2aX;uJGF{e2G7 MnHPNVDDqML3TR?= M3vjZVEhcA>? M3LvfmROW09? NWr3ZY9s\GWlcnXhd4V{KHSqZTDw[Y1mfHKneHXkMYlv\HWlZXSgUXNJOiCvUl7BJIFv\CCycn;0[YlvKGyndnXsdy=> M{T3W|I1PTNyNEe1
H520 NYnw[ZBMTnWwY4Tpc44hSXO|YYm= NYr3NHYzOTEEoNM1US=> M{exe|EzKGh? MVHEUXNQ MVHpcohq[mm2czDw[Y1mfHKneHXkMYVtcWOrdHXkJG1UUDJicILveIVqdiC|dHHibYxqfHl? NISwRnUzPDV|MES3OS=>
H1703 NWLQeHIzTnWwY4Tpc44hSXO|YYm= NYr5ZmFiOTEEoNM1US=> MlPkNVIhcA>? MYPEUXNQ NHLJdXpqdmirYnn0d{Bx\W2ndILlfIVlNWWuaXPpeIVlKE2VSEKgdJJwfGWrbjDzeIFjcWyrdIm= NULiZYgyOjR3M{C0O|U>
H520 NYXlWIQyTnWwY4Tpc44hSXO|YYm= MlixNVDDqML3TR?= NFfzXXk3KGh? M1;4W2ROW09? M1vDRpNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBt\X[nbIOgc4YhfWKrcYXpeIlvNWOxbnr1[4F1\WRiTWPINkBqdiCyZX3leJJmgGWmLYTy[YF1\WUEoHPlcIwhdGmwZR?= MWqyOFU{ODR5NR?=
H1703 NHjF[HNHfW6ldHnvckBCe3OjeR?= M2P0ZVExyqEEtV2= NUK2enpKPiCq MVXEUXNQ NVTwWlYxe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC3YnnxeYl1cW5vY3;ubpVo[XSnZDDNV2gzKGmwIIDlcYV1emW6ZXSteJJm[XSnZNMgZ4VtdCCuaX7l M1m3VVI1PTNyNEe1
MC3T3-E1 M2rhOWZ2dmO2aX;uJGF{e2G7 MojoNE4{NzNxM{Cg{txO MnTFNUBp MUPheJRmdnWjdHXzJHRPTi4QsT3pcoR2[2WmIF3NVE06KGW6cILld5Nqd25iaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= Mn\5NlQ2ODJ4OU[=
MC3T3-E1 NFzCPGlHfW6ldHnvckBCe3OjeR?= MoixN|Ah|ryP MXKxJIg> NXPMOJRl[XS2ZX71ZZRmeyCWTl[t{tEue3SrbYXsZZRm\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44> MlO3NlQ2ODJ4OU[=
HUVECs  MlLxSpVv[3Srb36gRZN{[Xl? NFn5O44yOMLiwsXN MkjYNUBp M1WyZolvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIFPYR2wyKHC{b3T1Z5Rqd25? MYCyOFQ5Pzl4NB?=
AGS  NHTUb5ZHfW6ldHnvckBCe3OjeR?= NIrnbocyOMLiwsXN MVuzNOKhdWmw NILEcopqdmirYnn0d{BKVC1zzsKtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKHB|OB?= NHW3bYIzPDR5OU[4NS=>
MKN-45 NHzmc2JHfW6ldHnvckBCe3OjeR?= MoPNNVDDqML3TR?= Mk\sN|DDqG2rbh?= NWj1UJBRcW6qaXLpeJMhUUxvMd8yMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{i= NV\2S3hXOjR2N{m2PFE>
AGS  M4f0bmZ2dmO2aX;uJGF{e2G7 NHzXOHAyOMLiwsXN MVKzNOKhdWmw M4fVXoF1fGWwdXH0[ZMhUUxvMd8yMYlv\HWlZXSgS2Eh[2WubDDtbYdz[XSrb36gZY5lKGmwdnHzbY9v MkjuNlQ1Pzl4OEG=
MKN-45 M2DOOWZ2dmO2aX;uJGF{e2G7 MVqxNOKhyrWP MX2zNOKhdWmw M{S3U4F1fGWwdXH0[ZMhUUxvMd8yMYlv\HWlZXSgS2Eh[2WubDDtbYdz[XSrb36gZY5lKGmwdnHzbY9v NWDReWxNOjR2N{m2PFE>
AGS  NXTSdmh7TnWwY4Tpc44hSXO|YYm= NXH3UpdkOTEEoNM1US=> Mn3IN|DDqG2rbh?= NEXPTWV{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDJcE0y|rJvaX7keYNm\CCPTWCyJIFv\CCPTWC5JI1TVkFiZYjwdoV{e2mxbh?= NUKxSVRROjR2N{m2PFE>
MKN-45 M3nKdWZ2dmO2aX;uJGF{e2G7 NEXld3cyOMLiwsXN M{S1WlMxyqCvaX6= MWHzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCLbD2x{tIucW6mdXPl[EBOVVB{IHHu[EBOVVB7IH3SUmEh\XiycnXzd4lwdg>? M3f3OlI1PDd7Nkix
DCs NUDhSYt7TnWwY4Tpc44hSXO|YYm= NUfHbndTOjEEoN88US=> MljFNeKhcA>? M2TnU4Rm[3KnYYPld{BKVC1zMjDwdo9lfWO2aX;u M4DoPFI1PDN2NkO2
HUVEC  M3TR[WZ2dmO2aX;uJGF{e2G7 NVHaeZpUOjBizsztxsA> NYT5PZZPPSCq M2qzV2ROW09? MnvqdoVlfWOnczDjfZRwc2mwZTDlfJBz\XO|aX;uJIxmfmWuczDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= NYTHTJR3OjRzOEmwOlI>
A 549 NV7CeoIzTnWwY4Tpc44hSXO|YYm= NYHmflN[PTBizszN MW[xJIg> MX\k[YNz\WG|ZYOgeIhmKGyndnXsJI9nKEmOLUlCpC=> MVSyOFE4QTZ6OB?=
H520  MVHGeY5kfGmxbjDBd5NigQ>? M2nyO|UwOTBizszN MkTINUBp M1TnUGROW09? M4rmT4Rm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs MX:yOFE{QDlyMx?=
H1703  NV;ESIpCTnWwY4Tpc44hSXO|YYm= M2CxPVUwOTBizszN NEPiZpQyKGh? NEDvSG1FVVOR Mo\Y[IVkemWjc3XzJG1UUDJicILveIVqdiCjczD3[YxtKGG|IH3SUmEhdGW4ZXzzJIlvKGenZnn0bY5q[i2neIDvd4VlKGOnbHy= NFvofoszPDF|OEmwNy=>
H520  MVHGeY5kfGmxbjDBd5NigQ>? NV3EVod1OTEEoNM1US=> NHnQXIkyOiCq MUfEUXNQ Mnjy[IVkemWjc3XzJG1UUDJibWLORUBidmRicILveIVqdiC|dHHibYxqfHliaX6g[4VncXSrbnniMZRz\WG2ZXSgUnNEVENiY3XscJM> NYDMelBIOjRzM{i5NFM>
H1703  M1vuU2Z2dmO2aX;uJGF{e2G7 MVGxNOKhyrWP M3\nWlEzKGh? NYPBWFJLTE2VTx?= Mnjm[IVkemWjc3XzJG1UUDJibWLORUBidmRicILveIVqdiC|dHHibYxqfHliaX6g[4VncXSrbnniMZRz\WG2ZXSgUnNEVENiY3XscJM> MkfQNlQyOzh7MEO=
MCF-7  MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\hcIZ4OTEEoN88US=> MYeyOOKhcA>? M4\4bYlvcGmkaYTzJJRp\SCFUkGwPE1qdmS3Y3XkJINmdGxiZHXheIg> MVOyOFEzQDh3Mx?=
HPAEpiCs NWPpc2hQTnWwY4Tpc44hSXO|YYm= NFHsUmoxNjFxMT:xNEDPxE1? NIXR[3QyKGh? M1LxSIlvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHPQUGEzyqCycn;0[YlvKGGwZDDtVm5CKGW6cILld5Nqd25? NF\WfpYzPDB4OUG1PC=>
podocytes NUHNfZNjTnWwY4Tpc44hSXO|YYm= NInn[mIyOMLizszN Mo[yNUBp NYrH[IJVcW6qaXLpeJMhXEeIzsKxMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{jNRXBMKGGwZDDFdosyNzMEoB?= M1WwPVI1ODN4MkGy
MCF-7 Mo[1SpVv[3Srb36gRZN{[Xl? MV6xNOKh|ryP M1v5ZVEhcA>? MnvvSG1UVw>? NF\zcHZz\WS3Y3XzJJRp\SCZQT3pcoR2[2WmIIDoc5NxcG:{eXzheIVlKHB|ODDNRXBM NXvmWZR1OjRyMUmwPVA>
MCF-7 Mly2SpVv[3Srb36gRZN{[Xl? M3nJdVExyqEQvF2= M17R[|I1KGh? Mk\pSG1UVw>? NYLud5M6cW6lcnXhd4V{KHSqZTDXRU1qdmS3Y3XkJIFxd3C2b4Ppdy=> M13VNlI1ODF7MEmw
HAPI NIT4RlJHfW6ldHnvckBCe3OjeR?= MWqxNE8zOC92MNMg{txO Mk\yNUBp M3jjTolvcGmkaYTzJHRETERvaX7keYNm\CCyM{ivTm5MKE2DUFugdIhwe3Cqb4L5cIF1cW:w MYmyN|k3QTF{MB?=
HAPI NYj3NHJlTnWwY4Tpc44hSXO|YYm= NHrrb4EzOMLizszNxsA> MmPTNUBp NHPwem9FVVOR NVWw[W92[XS2ZX71ZZRmeyCWQ1TEMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCrTl;TJIFv\CCycn;keYN1cW:w NInHZ3QzOzl4OUGyNC=>
HepG2 M134dGZ2dmO2aX;uJGF{e2G7 M3T5N|M2OCCwTR?= NGfybIQzPCCq NYraPYJ5cW6qaXLpeJMhfGinIHTl[5VmdGmwLXnu[JVk\WRiYXP0bZZifGmxbjDv[kBxOziPQWDL MVuyN|k{OzF7OB?=
AGS  MW\GeY5kfGmxbjDBd5NigQ>? NVjwO45bOTEEoN88US=> Mni1N|AhdWmw MoLPbY5pcWKrdIOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44h[W6mIHnubIljcXSrb36gc4YhTVKN MUOyN|g2ODl7NB?=
HepG2 NEC4dnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[5[GJYOC13MDFOwG0> MljuOFghcA>? NYnB[HdxcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M13oWFI{QDB5NUC4
BEL7404 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\hfJgxNTVyIN88US=> NHP5Z4k1QCCq MVXpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NH;6bmEzOzhyN{WwPC=>
HL7702 M3XJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX4NE02OCEQvF2= MWW0PEBp NFPuNpBqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MYiyN|gxPzVyOB?=
HepG2 MXrGeY5kfGmxbjDBd5NigQ>? M4DCXlAuPTBizszN NH3WV|MzPCCq NY\zOXp5cW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDwN|gh\G:5boP0doVidSCycn;0[YlveyCPQWDLRXBMOixiQWTGNkwhVVONMTDhcoQhUFOSMkegbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUO0U|lpOjN6MEe1NFg>
BEAS-2B MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTDWFBnOTBizszN MVyzNEBucW5? MnLudoV3\XK|ZYOgeIhmKGSnY4LlZZNmKG:oIHPlcIwhfmmjYnnsbZR6KGmwZIXj[YQh[nliSFPJ MnjmNlM4QDRyM{S=
BEAS-2B NY[1Z4JiS3m2b4TvfIl1gSCDc4PhfS=> MWOxNEDPxE1? M3fBNlMxKG2rbh?= MXHpcohq[mm2ZXSgeIhmKGmwY4LlZZNmKGmwIFzETEBidmRiSVytPEBmgHC{ZYPzbY9v M1\vTFI{Pzh2MEO0
BEAS-2B M2DkZmZ2dmO2aX;uJGF{e2G7 Mkf5NVAh|ryP NVrzU2IyOzBibXnu MXfk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iClYYPwZZNmNTNuIFLh[EBidmRiZnHz MlzyNlM4QDRyM{S=
H9c2  M2D2emZ2dmO2aX;uJGF{e2G7 MkHvNE4xOS9yLkGvNUDPxE1? M1j2eVEhcA>? NGH3PHVifHSnboXheIV{KFSQRj5OtU1qdmS3Y3XkJG1OWC17IHX4dJJme3Orb36sJI1TVkFibHX2[Yx{NCCjbnSgdJJwdW:2ZYKgZYN1cX[rdIm= MVeyN|c4PDJ3Mh?=
H9c2  NILHSXRHfW6ldHnvckBCe3OjeR?= M{HSWFEh|ryP NG[0c4cyKGh? NUnIeoxtemWmdXPld{BVVkZvzsGg[Ilz\WO2bImgd5RqdXWuYYTl[EBxOzhiTVHQT{BxcG:|cHjvdplt[XSrb36= NH;pOlQzOzd5NEK1Ni=>
U937 MYjGeY5kfGmxbjDBd5NigQ>? MU[xNOKh|ryPwrC= NXvvRlRzOSCq NFWwZlJi[nKxZ3H0[ZMhfGinIHPh[oZmcW6nIHXm[oVkfCCxbjDNT3AuOSCjbnSgVHAzSWQQsTDtVm5CKHS{YX7zZ5JqeHSrb37hcEBt\X[nbIO= MmixNlM4ODd|OEe=
U937 MVLGeY5kfGmxbjDBd5NigQ>? NYT6NYczOTEEoN88UeKh M3X6R|EhcA>? Mm\3ZYJzd2ejdHXzJINi\m[naX7lMYlv\HWlZXSgUWtRNTFiZH;3ck1z\We3bHH0bY9vKGGwZDDQVFJC[87zIIXwMZJm\3WuYYTpc44> M{T3OVI{PzB5M{i3
U937 MU\GeY5kfGmxbjDBd5NigQ>? MlXCNVDDqM7:TdMg NX7oPGZvOSCq NYjpOZp{e3WycILld5NmeyClLVr1ckBidmRiQ2LFRkBxcG:|cHjvdplt[XSrb36gbY4h[2GoZnXpcoUufHKnYYTl[EBk\Wyuc9Mg NEizUFczOzdyN{O4Oy=>
A549 NGK5bYVHfW6ldHnvckBCe3OjeR?= NEDUTIMxNjNxMz:zNEDPxE1? NGjTVG4yKGh? NY\hUVVLe2mpbnnmbYNidnSueTDheJRmdnWjdHXzJGFVWM7|Uz3t[YRq[XSnZDDDU3guOiCycn;0[YlvKGGwZDDtVm5CKGW6cILld5Nqd25iYX7kJJBzd22xdHXyJIFkfGm4aYT5xsA> NF7rR4gzOzZ6ME[3OC=>
A549 MlzDSpVv[3Srb36gRZN{[Xl? M3XqOVExyqEQvF5CpC=> MYSwMVMxKG2rbh?= NF76bG1qdmirYnn0d{BCXFEQs2OgbY5lfWOnZDDwOFIweDR2IF3BVGsh[W6mIICzPEBOSVCNIIDoc5NxcG:{eXzheIlwdg>? MUOyN|Y5ODZ5NB?=
A549 MoKySpVv[3Srb36gRZN{[Xl? NUS3bFZUOTEEoN88UeKh MYmxJIg> NUe0fFhJcW6qaXLpeJMhSVSSzsPTJIlv\HWlZXSgUmYu|rqEIIC2OUB{fWK3bnn0JJBpd3OyaH;yfYxifGmxbjDhcoQhVkZvzsrCJJBzd22xdHXyJIFkfGm4aYT5 NHfRZXgzOzZ6ME[3OC=>
A549 MWrGeY5kfGmxbjDBd5NigQ>? NWTDUFJ5OTEEoN88UeKh MkjENUBp NYnO[ZNDemWmdXPld{BCXFEQs2Otd5RqdXWuYYTl[EBkWEyDMjDwbI9{eGixconsZZRqd28EoB?= Mlf0NlM3QDB4N{S=
A549 MV3GeY5kfGmxbjDBd5NigQ>? M4G0[FExyqEQvF5CpC=> MWixJIg> MYXy[YR2[2W|IFHUVO6{Wy2nbnjhcoNm\CCnbor5cYF1cWNiYXP0bZZqfHlib3[gZ3BNSTMEoB?= MmnsNlM3QDB4N{S=
PC12 MY\GeY5kfGmxbjDBd5NigQ>? NHH3fGkyOC9{MD:0NEDPxE1? NHL4d2oyyqCq M1;YeolvcGmkaYTzJGpPUyCjbnSgdFM5 NEjIcnozOzV6NEO1Oy=>
HK-2 M{fIZmFxd3C2b4Ppd{BCe3OjeR?= NYDYS2hJOjEEoN88US=> MnzQNlQhcA>? MmjQbY5pcWKrdIOgSXJMKGGwZDDwN|hOSVCN M1WyO|I{PTR|MUWx
H9c2 MV3GeY5kfGmxbjDBd5NigQ>? NXO2d4VQOcLizszN NUnsb3dbOSCq NGfBXIdz\WS3Y3XzJHRPTi4QsT3pcoR2[2WmIF3NVE06KG2UTlGgcIV3\Wy|IHHu[EBxem:vb4TldkBi[3Srdnn0fS=> NYHMOnZnOjN|NUO2PVk>
H9c2 NUDpc2tDTnWwY4Tpc44hSXO|YYm= MWixxsDPxE1? M3jKPFEhcA>? MYTy[YR2[2W|IGTOSk3PuS2nbnjhcoNm\CCDUD2xJJBzd22xdHXyJIFkfGm4aYT5 NIfW[IEzOzN3M{[5PS=>
H1650  M4P3V2Z2dmO2aX;uJGF{e2G7 NEXkNGUyOMLizszNxsA> NFrBNmkyKGh? NXLY[GJbTE2VTx?= NWPKdFQ4\GWlcnXhd4V{KGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHNib3[gSXJESzFiaX6gdIFkdGm2YYjlcE1mgHCxc3XkxsBk\Wyucx?= MV:yN|IzQDZ7Nh?=
H1703 M1;OcWZ2dmO2aX;uJGF{e2G7 NX;lPWJpOTEEoN88UeKh NXP1UXQ4OSCq M3q1TmROW09? M1P6coRm[3KnYYPld{Bjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yx{KG:oIFXSR2MyKGmwIIDhZ4xqfGG6ZXyt[Zhxd3OnZNMgZ4VtdHN? NIewUHgzOzJ{OE[5Oi=>
H1650  NIXzVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:xNOKh|ryPwrC= NWe2WZFzOSCq NFOyN3BFVVOR MY\lcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 M1qzdVI{OjJ6Nkm2
H1703 NEP1ZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\OOVExyqEQvF5CpC=> MXWxJIg> NVPlSolGTE2VTx?= NFz3W3hmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[3m2b4TvfIlkcXS7 NULicGxvOjN{Mki2PVY>

... Click to View More Cell Line Experimental Data

In vivo Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. [5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. [8]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro kinase assays:

The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research:

[2]

+ Expand
  • Cell lines: Jurkat, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 12.5 μg
  • Administration: Administered via i.d.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (199.19 mM)
Ethanol 12 mg/mL (36.21 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 331.34
Formula

C20H14N3OF

CAS No. 152121-30-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy SB202190 (FHPI) | SB202190 (FHPI) supplier | purchase SB202190 (FHPI) | SB202190 (FHPI) cost | SB202190 (FHPI) manufacturer | order SB202190 (FHPI) | SB202190 (FHPI) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID